Cargando…

A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer

LESSONS LEARNED. Ideally, patients should have access to an oral formulation of paclitaxel, as well as an intravenous formulation, to allow development of regimens exploring alternate schedules and to avoid reactions to Cremophor EL (BASF Corp., Ludwigshafen, Germany, https://www.basf.com). DHP107 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Min‐Hee, Ryoo, Baek‐Yeol, Kim, Tae Won, Kim, Sung Bae, Lim, Hyeong‐Seok, Bae, Kyun‐Seop, Park, Sook Ryun, Jo, Yeong‐Woo, Cho, Hyun Ju, Kang, Yoon‐Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330712/
https://www.ncbi.nlm.nih.gov/pubmed/28196905
http://dx.doi.org/10.1634/theoncologist.2016-0273